Longitudinal effects of Nucleos(t)ide analogue therapy in chronic hepatitis B patients and the utility of non-invasive fibrosis markers during treatment: A single-center experience for up to 17 years.
Fibrosis
Hepatitis B
Inflammation
Non-invasive markers of fibrosis
Nucleoside analogues
Journal
Antiviral research
ISSN: 1872-9096
Titre abrégé: Antiviral Res
Pays: Netherlands
ID NLM: 8109699
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
25
01
2019
revised:
16
05
2019
accepted:
19
05
2019
pubmed:
28
5
2019
medline:
13
6
2020
entrez:
25
5
2019
Statut:
ppublish
Résumé
Fibrosis regression has been associated with nucleoside analogue (NA) treatment in chronic hepatitis B (CHB) patients. Although non-invasive fibrosis markers have been evaluated in CHB, their utility for monitoring on-treatment histologic regression has not been evaluated. To characterize improvements in disease severity and the utility of non-invasive biomarkers in CHB NA treated patients. Histology, labs, AST-to-platelet ratio index, and Fibrosis-4 (Fib-4) from treatment-naïve CHB patients were evaluated at baseline and longitudinally. Relative change from baseline to various time points during treatment were evaluated. Correlative analysis of APRI and Fib-4 with histology was performed longitudinally. 80 CHB patients (84% male, median age 45 (IQR 32, 54)) with histology up to 17 years (median 6(IQR 3.9, 8.0)) years were studied. Median baseline Ishak fibrosis was 3 (IQR 2, 4), histologic activity index (HAI) inflammation was 9 (IQR 7, 11), and AUROC of fibrosis markers for detecting cirrhosis (Ishak ≥ 5) was >0.64. HAI improved at a rate of 54% during year 1 and 37% in year 2, both greater than in the remaining follow-up periods. Within the first year, fibrosis improved by 35%, greater than all other time periods. Non-invasive biomarkers began to correlate with histology beyond 4 years (APRI: 4-6 years: r = 0.33, p = 0.03; ≥6 years: r = 0.41, p = 0.009; Fib-4: ≥6 years: r = 0.35, p = 0.03). Early dynamic changes in histology occur in CHB patients on NA followed by linear improvements. Non-invasive fibrosis biomarkers do not capture these dynamic changes and may demonstrate clinical utility beyond 4 years of treatment.
Sections du résumé
BACKGROUND
Fibrosis regression has been associated with nucleoside analogue (NA) treatment in chronic hepatitis B (CHB) patients. Although non-invasive fibrosis markers have been evaluated in CHB, their utility for monitoring on-treatment histologic regression has not been evaluated.
AIMS
To characterize improvements in disease severity and the utility of non-invasive biomarkers in CHB NA treated patients.
METHODS
Histology, labs, AST-to-platelet ratio index, and Fibrosis-4 (Fib-4) from treatment-naïve CHB patients were evaluated at baseline and longitudinally. Relative change from baseline to various time points during treatment were evaluated. Correlative analysis of APRI and Fib-4 with histology was performed longitudinally.
RESULTS
80 CHB patients (84% male, median age 45 (IQR 32, 54)) with histology up to 17 years (median 6(IQR 3.9, 8.0)) years were studied. Median baseline Ishak fibrosis was 3 (IQR 2, 4), histologic activity index (HAI) inflammation was 9 (IQR 7, 11), and AUROC of fibrosis markers for detecting cirrhosis (Ishak ≥ 5) was >0.64. HAI improved at a rate of 54% during year 1 and 37% in year 2, both greater than in the remaining follow-up periods. Within the first year, fibrosis improved by 35%, greater than all other time periods. Non-invasive biomarkers began to correlate with histology beyond 4 years (APRI: 4-6 years: r = 0.33, p = 0.03; ≥6 years: r = 0.41, p = 0.009; Fib-4: ≥6 years: r = 0.35, p = 0.03).
CONCLUSION
Early dynamic changes in histology occur in CHB patients on NA followed by linear improvements. Non-invasive fibrosis biomarkers do not capture these dynamic changes and may demonstrate clinical utility beyond 4 years of treatment.
Identifiants
pubmed: 31125632
pii: S0166-3542(19)30048-8
doi: 10.1016/j.antiviral.2019.05.007
pmc: PMC6620142
mid: NIHMS1530438
pii:
doi:
Substances chimiques
Biomarkers
0
Nucleosides
0
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
61-67Subventions
Organisme : Intramural NIH HHS
ID : Z99 DK999999
Pays : United States
Informations de copyright
Published by Elsevier B.V.
Références
N Engl J Med. 2001 Feb 15;344(7):495-500
pubmed: 11172192
J Gastroenterol Hepatol. 2011 Apr;26(4):628-38
pubmed: 21323729
J Gastroenterol Hepatol. 2015 Dec;30(12):1775-81
pubmed: 26095700
Arch Pathol Lab Med. 2000 Nov;124(11):1599-607
pubmed: 11079009
N Engl J Med. 2003 Feb 27;348(9):808-16
pubmed: 12606735
Clin Gastroenterol Hepatol. 2018 Oct;16(10):1641-1649.e6
pubmed: 29505905
Comp Hepatol. 2004 Sep 23;3(1):8
pubmed: 15387887
Clin Gastroenterol Hepatol. 2019 Jul;17(8):1641-1642.e1
pubmed: 30268565
Semin Liver Dis. 2010 Aug;30(3):296-301
pubmed: 20665381
Antivir Ther. 2004 Oct;9(5):729-32
pubmed: 15535410
Gastroenterology. 2003 Jan;124(1):105-17
pubmed: 12512035
Lancet. 2014 Dec 6;384(9959):2053-63
pubmed: 24954675
N Engl J Med. 2006 Mar 9;354(10):1011-20
pubmed: 16525138
Ultrasound Med Biol. 2003 Dec;29(12):1705-13
pubmed: 14698338
Hepatology. 2018 Apr;67(4):1560-1599
pubmed: 29405329
Clin Res Hepatol Gastroenterol. 2013 Apr;37(2):152-8
pubmed: 23391746
Hepatology. 1981 Sep-Oct;1(5):431-5
pubmed: 7308988
Am J Gastroenterol. 2017 Oct;112(10):1625
pubmed: 28895581
Hepatol Int. 2015 Apr;9(2):243-50
pubmed: 25788199
N Engl J Med. 1999 Oct 21;341(17):1256-63
pubmed: 10528035
Liver Int. 2014 Feb;34 Suppl 1:91-6
pubmed: 24373084
PLoS One. 2014 Aug 28;9(8):e105728
pubmed: 25165830
Dig Dis Sci. 2015 Jan;60(1):260-8
pubmed: 25179493
Eur J Pharmacol. 2017 Jul 5;806:105-109
pubmed: 28414057
J Hepatol. 1995 Jun;22(6):696-9
pubmed: 7560864
Biochim Biophys Acta. 2013 Jul;1832(7):876-83
pubmed: 23149387
Lancet. 2013 Feb 9;381(9865):468-75
pubmed: 23234725
J Hepatol. 2016 Apr;64(4):773-80
pubmed: 26626497
Liver Int. 2010 Apr;30(4):546-53
pubmed: 20074094
Liver Int. 2017 Jan;37 Suppl 1:45-51
pubmed: 28052621
Scand J Clin Lab Invest. 2016;76(2):133-42
pubmed: 26878877
J Gastroenterol Hepatol. 2015 Feb;30(2):372-8
pubmed: 25167956
J Hepatol. 2015 Mar;62(3):526-32
pubmed: 25450709
Hepatology. 2002 Nov;36(5 Suppl 1):S152-60
pubmed: 12407589
Hepatology. 2006 Jun;43(6):1317-25
pubmed: 16729309
Hepatology. 2003 Aug;38(2):518-26
pubmed: 12883497
World J Gastroenterol. 2014 Oct 28;20(40):14568-80
pubmed: 25356021